DGIdb - VINBLASTINE Drug Record

VINBLASTINE chembl:CHEMBL159 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-47842
[3H]-VINBLASTINE
VELBAN
VINBLASTINE

Drug Info:

Drug Class	antineoplastic agents
Year of Approval	1965
Drug Categories	bsep/abcb11 inhibitors
FDA Approval	1965
Drug Class	small molecule
Drug Indications	Antineoplastic Agents
Drug Categories	bsep/abcb11 substrates
Drug Categories	bsep/abcb11 substrates with narrow therapeutic index
Drug Categories	cardiotoxic antineoplastic agents
Drug Categories	cytochrome p-450 cyp3a inducers
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a4 substrates with a narrow therapeutic index
Drug Categories	cytochrome p-450 enzyme inducers
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	narrow therapeutic index drugs
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	p-glycoprotein inducers
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	p-glycoprotein substrates with narrow therapeutic index

(6 More Sources)

Publications:

Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem
Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett
Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
Jordan et al., 1998, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle., Med Res Rev
Correia, 1991, Effects of antimitotic agents on tubulin-nucleotide interactions., Pharmacol. Ther.
Jordan et al., 2007, How do microtubule-targeted drugs work? An overview., Curr Cancer Drug Targets
Islam et al., 2004, Microtubulin binding sites as target for developing anticancer agents., Mini Rev Med Chem
Gupta et al., 2003, Antimicrotubular drugs binding to vinca domain of tubulin., Mol. Cell. Biochem.
Vogelzang et al., 1982, Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors., Cancer Res.
Vacca et al., 1999, Antiangiogenesis is produced by nontoxic doses of vinblastine., Blood
Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Aglietta et al., 2000, Short term treatment with Escherichia coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease., Cancer
Tishler et al., 1996, The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1., Br. J. Cancer Suppl.
Seidman et al., 1992, Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer., J. Urol.
Martínez-Campa et al., 2006, Effect of vinca alkaloids on ERalpha levels and estradiol-induced responses in MCF-7 cells., Breast Cancer Res. Treat.
Bene et al., 2004, Subcellular localization as a limiting factor for utilization of decoy oligonucleotides., Nucleic Acids Res.
Brantley-Finley et al., 2003, The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide., Biochem. Pharmacol.
Duan et al., 2007, Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest., Biochem. Pharmacol.
Obey et al., 2005, Role of c-Jun in cellular sensitivity to the microtubule inhibitor vinblastine., Biochem. Biophys. Res. Commun.
Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.
Sheridan et al., 1996, Microtubules regulate pulmonary vascular smooth muscle contraction., J. Surg. Res.
Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
Warberg et al., 1980, Ion-induced release of LHRH, TRH and alpha-MSH from hypothalamic synaptosomes and its inhibition by vinblastine., Pflugers Arch.

VINBLASTINE TUBG1

Interaction Score: 9.74

Interaction Types & Directionality:

adduct

Interaction Info:

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank
VINBLASTINE TUBD1

Interaction Score: 9.74

Interaction Types & Directionality:

adduct

Interaction Info:

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank
VINBLASTINE TUBE1

Interaction Score: 9.74

Interaction Types & Directionality:

adduct

Interaction Info:

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank
VINBLASTINE PTHLH

Interaction Score: 1.62

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9784008

Sources:
NCI
VINBLASTINE CGA

Interaction Score: 1.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6181870

Sources:
NCI
VINBLASTINE TRH

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6774314

Sources:
NCI
VINBLASTINE ABCB4

Interaction Score: 0.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7918493

Sources:
NCI
VINBLASTINE TUBA1A

Interaction Score: 0.3

Interaction Types & Directionality:

adduct

Interaction Info:

PMIDs:
9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources:
DTC DrugBank
VINBLASTINE TUBB

Interaction Score: 0.28

Interaction Types & Directionality:

adduct

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources:
DTC DrugBank GuideToPharmacology
VINBLASTINE JUN

Interaction Score: 0.21

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
16555127 15498923 12907245 17126817 16111654

Sources:
DrugBank
VINBLASTINE TUBB4A

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3C

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB2A

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
23708010 23916255

Sources:
TEND DTC TdgClinicalTrial
VINBLASTINE KLK3

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1371564

Sources:
NCI
VINBLASTINE CDKN1A

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8763853

Sources:
NCI
VINBLASTINE TBXA2R

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8632653

Sources:
NCI
VINBLASTINE TUBB4B

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC TTD
VINBLASTINE GSTM1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23323945

Sources:
PharmGKB
VINBLASTINE TUBB8

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3E

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB2B

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA3D

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB6

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA1B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA1C

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBA4A

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE TUBB3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE MMP2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10590059

Sources:
NCI
VINBLASTINE TUBB1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23708010 23916255

Sources:
DTC
VINBLASTINE CSF2

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10640980

Sources:
NCI
VINBLASTINE NF1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Chemotherapy;BCR-ABL inhibitor 2nd gen

combination therapy Vinblastine;Nilotinib

Alteration NF1:.

PMIDs:
None found

Sources:
CGI
VINBLASTINE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21348461 20363635

Sources:
DTC
VINBLASTINE NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
VINBLASTINE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9187528

Sources:
PharmGKB
VINBLASTINE GMNN

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00570

Version: 5.1.7

Alternate Names:

VINBLASTINE DrugBank Drug Name

865-21-4 CAS Number

Blastivin Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories alkaloids

Publications:

Jordan et al., 1998, Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle., Med Res Rev

Correia, 1991, Effects of antimitotic agents on tubulin-nucleotide interactions., Pharmacol. Ther.

Jordan et al., 2007, How do microtubule-targeted drugs work? An overview., Curr Cancer Drug Targets

TEND: VINBLASTINE
- Version: 01-August-2011
Alternate Names:

VINBLASTINE Primary Drug Name

Drug Info:

Year of Approval 1965

Drug Class antineoplastic agents

Publications:
TdgClinicalTrial: VINBLASTINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1965

Publications:

NCI: VINBLASTINE

Version: 14-September-2017

Alternate Names:

C930 NCI drug code

Drug Info:

Publications:

Bornmann et al., 1994, Analysis of drug transport kinetics in multidrug-resistant cells using a novel coumarin-vinblastine compound., Biochemistry

Gorczyca et al., 1992, Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide., Cancer Res.

Gröne et al., 1998, Regulation of parathyroid hormone-related protein expression in a canine squamous carcinoma cell line by colchicine., Exp. Toxicol. Pathol.

DTC: VINBLASTINE

Version: 02-September-2020

Alternate Names:

CHEMBL159 ChEMBL Drug ID

Drug Info:

Publications:

Zheng J et al., 2013, Elaboration of thorough simplified vinca alkaloids as antimitotic agents based on pharmacophore similarity., Eur J Med Chem

Cheng YY et al., 2013, Design, synthesis, and mechanism of action of 2-(3-hydroxy-5-methoxyphenyl)-6-pyrrolidinylquinolin-4-one as a potent anticancer lead., Bioorg Med Chem Lett

Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod

PharmGKB: vinblastine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma

TTD: Vinblastine
- Version: 2020.06.01
Alternate Names:

D0W9MM TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 178103457
- Version: 29-September-2020
Alternate Names:

VINBLASTINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL159
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
CGI: Vinblastine
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	Inhibition
Endogenous Drug?	False
Direct Interaction?	True

Drug family	Chemotherapy;BCR-ABL inhibitor 2nd gen
combination therapy	Vinblastine;Nilotinib
Alteration	NF1:.

VINBLASTINE	DrugBank Drug Name
865-21-4	CAS Number
Blastivin	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	alkaloids

adduct
inhibitor (inhibitory)

VINBLASTINE Drug Record

VINBLASTINE chembl:CHEMBL159 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: adduct

Interaction Info:

PMIDs: 9664292 1818332 18220533 15579115 14619954

Sources: DrugBank

Interaction Types & Directionality: adduct

Interaction Info:

PMIDs: 9664292 1818332 18220533 15579115 14619954

Sources: DrugBank

Interaction Types & Directionality: adduct

Interaction Info:

PMIDs: 9664292 1818332 18220533 15579115 14619954

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9784008

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6181870

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6774314

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7918493

Sources: NCI

Interaction Types & Directionality: adduct

Interaction Info:

PMIDs: 9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources: DTC DrugBank

Interaction Types & Directionality: adduct inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Inhibition Endogenous Drug? False Direct Interaction? True

PMIDs: 9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources: DTC DrugBank GuideToPharmacology

Interaction Types & Directionality: other/unknown

Interaction Info:

PMIDs: 16555127 15498923 12907245 17126817 16111654

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 23708010 23916255

Sources: TEND DTC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1371564

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8763853

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8632653

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Sources: DTC TTD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23323945

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23708010 23916255

Interaction Types & Directionality:

adduct

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank

Interaction Types & Directionality:

adduct

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank

Interaction Types & Directionality:

adduct

PMIDs:
9664292 1818332 18220533 15579115 14619954

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
9784008

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6181870

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
6774314

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7918493

Sources:
NCI

Interaction Types & Directionality:

adduct

PMIDs:
9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources:
DTC DrugBank

Interaction Types & Directionality:

adduct

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? True

PMIDs:
9664292 23708010 1818332 18220533 15579115 23916255 14619954

Sources:
DTC DrugBank GuideToPharmacology

Interaction Types & Directionality:

other/unknown

PMIDs:
16555127 15498923 12907245 17126817 16111654

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
23708010 23916255

Sources:
TEND DTC TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
1371564

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8763853

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8632653

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC TTD

Interaction Types & Directionality:

n/a

PMIDs:
23323945

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
23708010 23916255

Sources:
DTC